Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis

Respir Res. 2011 Dec 29;12(1):161. doi: 10.1186/1465-9921-12-161.

Abstract

Background: Relationships between improvements in lung function and other clinical outcomes in chronic obstructive pulmonary disease (COPD) are not documented extensively. We examined whether changes in trough forced expiratory volume in 1 second (FEV(1)) are correlated with changes in patient-reported outcomes.

Methods: Pooled data from three indacaterol studies (n = 3313) were analysed. Means and responder rates for outcomes including change from baseline in Transition Dyspnoea Index (TDI), St. George's Respiratory Questionnaire (SGRQ) scores (at 12, 26 and 52 weeks), and COPD exacerbation frequency (rate/year) were tabulated across categories of ΔFEV(1). Also, generalised linear modelling was performed adjusting for covariates such as baseline severity and inhaled corticosteroid use.

Results: With increasing positive ΔFEV(1), TDI and ΔSGRQ improved at all timepoints, exacerbation rate over the study duration declined (P < 0.001). Individual-level correlations were 0.03-0.18, but cohort-level correlations were 0.79-0.95. At 26 weeks, a 100 ml increase in FEV(1) was associated with improved TDI (0.46 units), ΔSGRQ (1.3-1.9 points) and exacerbation rate (12% decrease). Overall, adjustments for baseline covariates had little impact on the relationship between ΔFEV(1) and outcomes.

Conclusions: These results suggest that larger improvements in FEV(1) are likely to be associated with larger patient-reported benefits across a range of clinical outcomes.

Trial registration: ClinicalTrials.gov NCT00393458, NCT00463567, and NCT00624286.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-2 Receptor Agonists / therapeutic use*
  • Aged
  • Bronchodilator Agents / therapeutic use*
  • Clinical Trials, Phase III as Topic
  • Evidence-Based Medicine
  • Female
  • Forced Expiratory Volume
  • Humans
  • Indans / therapeutic use*
  • Linear Models
  • Lung / drug effects*
  • Lung / physiopathology
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Pulmonary Disease, Chronic Obstructive / diagnosis
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Pulmonary Disease, Chronic Obstructive / physiopathology
  • Quinolones / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Recovery of Function
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome

Substances

  • Adrenergic beta-2 Receptor Agonists
  • Bronchodilator Agents
  • Indans
  • Quinolones
  • indacaterol

Associated data

  • ClinicalTrials.gov/NCT00393458
  • ClinicalTrials.gov/NCT00463567
  • ClinicalTrials.gov/NCT00624286